Safety, tolerability and efficacy of the addition of bevacizumab to oxaliplatin/fluoropyrimidine regimens as first-line treatment of metastatic colorectal cancer (mCRC): Results of TREE 2 cohort of the TREE study

被引：0
|
作者：
Hochster, H.
Hart, L.
Ramanathan, R. K.
Hainsworth, J.
Griffing, S.
Mass, R.
Nagarwala, Y.
Jirau-Lucca, G.
Shpilsky, A.
Childs, B. H.
机构：
[1] NYU, Inst Canc, New York, NY USA
[2] Florida Canc Specialist, Ft Myers, FL USA
[3] Univ Pittsburgh, Ctr Canc, Pittsburgh, PA 15260 USA
[4] Sarah Cannon Canc Ctr, Nashville, TN USA
[5] Genentech Inc, San Francisco, CA USA
[6] Sanofi Aventis, Bridgewater, MA USA
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：173 / 173
页数：1
相关论文
共 50 条
  • [21] The study of efficacy and safety of chemotherapy plus bevacizumab with oxaliplatin stop-and-go strategy in first-line treatment for metastatic colorectal cancer.
    Takano, Nao
    Nakayama, Goro
    Kodera, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [22] A phase I study of sorafenib with FOLFIRI as first-line therapy for metastatic colorectal cancer (mCRC): Safety and efficacy results
    Maroun, Jean Alfred
    Jonker, Derek J.
    Cripps, M. Christine
    Asmis, Timothy R.
    Goel, Rakesh
    Goodwin, Rachel Anne
    Marginean, Horia
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer
    Whyte, S.
    Pandor, A.
    Stevenson, M.
    Rees, A.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 47 - 53
  • [24] Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer
    Tsutsumi, Soichi
    Fujii, Takaaki
    Yamaguchi, Satoru
    Suto, Toshinaga
    Yajima, Reina
    Morita, Hiroki
    Kato, Toshihide
    Asao, Takayuki
    Kuwano, Hiroyuki
    HEPATO-GASTROENTEROLOGY, 2014, 61 (131) : 633 - 637
  • [25] A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer
    R López
    M Salgado
    M Reboredo
    C Grande
    J C Méndez
    M Jorge
    C Romero
    G Quintero
    J de la Cámara
    S Candamio
    British Journal of Cancer, 2010, 103 : 1536 - 1541
  • [26] A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer
    Lopez, R.
    Salgado, M.
    Reboredo, M.
    Grande, C.
    Mendez, J. C.
    Jorge, M.
    Romero, C.
    Quintero, G.
    de la Camara, J.
    Candamio, S.
    BRITISH JOURNAL OF CANCER, 2010, 103 (10) : 1536 - 1541
  • [27] Impact of the addition of bevacizumab, oxaliplatin or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients.
    Landre, Thierry
    Aparicio, Thomas
    Ghebriou, Djamel
    Nicolas, Patrick
    Taleb, Cherifa
    Chouahnia, Kader
    Zelek, Laurent H.
    Des Guetz, Gaetan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] EFFECTIVENESS AND SAFETY OF FIRST-LINE BEVACIZUMAB PLUS FOLFIRI IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Pinto, Ana Catarina
    Teixeira, Margarida
    Bonito, Nuno
    Jacinto, Paula
    Ribeiro, Joao
    Gervasio, Helena
    ANNALS OF ONCOLOGY, 2011, 22 : v98 - v98
  • [29] The efficacy and safety of XELOX plus bevacizumab with oxaliplatin stop-and-go strategy in first-line treatment for metastatic colorectal cancer: CCOG 0902 study
    Watanabe, Takuya
    Nakayama, Goro
    Ishigure, Kiyoshi
    Hayashi, Naomi
    Yaguchi, Toyohisa
    Kojima, Hiroshi
    Tsuboi, Kenji
    Ito, Akihiro
    Deguchi, Tomohiro
    Sekiya, Masanori
    Tanaka, Chie
    Ando, Yuichi
    Ohashi, Norifumi
    Kodera, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [30] Bi-weekly XELOX (capecitabine/oxaliplatin) plus bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): PHOENIX trial
    Nagata, N.
    Okada, T.
    Okazaki, S.
    Sato, S.
    Kin, H.
    Nakamura, M.
    Kunieda, K.
    Oba, K.
    Sakamoto, J.
    Mishima, H.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S559 - S559
12345